MRNA vaccine takes on shingles: could it beat shingrix?
NCT ID NCT07285265
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new mRNA vaccine called ABO1108 to prevent shingles in adults aged 40 and above. Around 180 healthy volunteers will receive two shots of either the new vaccine at different doses, a placebo, or the existing Shingrix vaccine. The main goal is to check safety and how well the body's immune system responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABO1108 (mRNA vaccine for shingles)
- What this could lead to
- If successful, this could lead to a new, potentially more effective or easier-to-store shingles vaccine for older adults.
- What could go wrong
- This is an early Phase 1 trial with only 180 participants, so safety and immune response are still being tested. It may not prove effective or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VARICELLA-ZOSTER VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rongshui Miao Autonomous County Center for Disease Control and Prevention
Liuzhou, Rongshui, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.